Non-Stimulant ADHD Medications and Semaglutide Safety Non-stimulant ADHD treatments, such as atomoxetine (Strattera), guanfacine, and clonidine, operate through different neurochemical pathways than stimulants and show even fewer interaction concerns with semaglutide
While preclinical studies have investigated the effects of GLP-1RAs on nicotine, alcohol, cocaine, or opioids [20,21,22,23], to our knowledge no studies have been reported on their effects of tetrahydrocannabinol (THC), the major psychoactive component in cannabis
A consultation confirms suitability
Notably, IL-6 levels are significantly higher in patients with SAP than in those with MAP, supporting its potential role as a biomarker for early prediction and severity discrimination in AP
Benefits Beyond Weight Loss: Metabolic and Cardiovascular Health Cardiovascular risk reduction semaglutide reduced major cardiovascular events by 20% in the SELECT trial Blood sugar control significant HbA1c reductions in patients with type 2 diabetes or prediabetes Reduced liver fat growing evidence supports GLP-1 therapy for NAFLD and MASLD Sleep apnea improvement tirzepatide demonstrated 63% reduction in apnea-hypopnea index (2024 NEJM trial) Fatty Liver Disease & GLP-1 Therapy Patients with NAFLD/MASLD may see significant improvement with GLP-1 treatment
Once in circulation, it activates two receptors that the gut normally talks to after a meal: GIP and GLP-1
